NasdaqGS:NVCRMedical Equipment
NovoCure (NVCR) Could Be 42% Undervalued On Mixed TRIDENT Trial Results
NovoCure (NVCR) stock is in focus after the company reported topline Phase 3 TRIDENT data showing no statistically significant overall survival benefit from earlier initiation of Tumor Treating Fields in newly diagnosed glioblastoma.
See our latest analysis for NovoCure.
For context, NovoCure’s share price has been volatile, with a 5.39% 7 day share price return and a 37.19% 90 day share price return, but a 1 year total shareholder return that declined 11.99%, suggesting recent momentum...

